Genentech takes the health and safety of our patients, customers, employees and local communities very seriously, and we are actively responding to the global COVID-19 pandemic. For more, please visit our COVID-19 response page.

Focus on Neuroscience

Neurological and psychiatric disorders cause immense suffering and societal strain across the globe and their treatment remains a severe unmet need. Genentech is working to discover and develop transformative medicines for patients with major diseases of the nervous system. Presently we're focused on neurodegenerative disorders such as Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis (ALS), as well as pain.

By using a multidisciplinary approach and a wide range of technologies, we seek to unravel the fundamental mechanisms underlying the biology and the diseases of the nervous system, and to translate these discoveries into innovative therapies for neurological disorders.

Key Publications

eLife, April 2017
Dual leucine zipper kinase-dependent PERK activation contributes to neuronal degeneration following insult
Neuron, March 2017
Positive Allosteric Modulators of GluN2A-Containing NMDARs with Distinct Modes of Action and Impacts on Circuit Function
Cell Report, August 2016
Antibody-Mediated Targeting of Tau In Vivo Does Not Require Effector Function and Microglial Engagement
Neuron, July 2016
TREM2 Binds to Apolipoproteins, Including APOE and CLU/APOJ, and Thereby Facilitates Uptake of Amyloid-Beta by Microglia
Nature Communications, April 2016
Untangling the brain's neuroinflammatory and neurodegenerative transcriptional responses
Nature, June 2014
The mitochondrial deubiquitinase USP30 opposes parkin-mediated mitophagy